A nasal spray for treatment-resistant depression has delivered strong clinical results and rekindled investor hopes.

Compared with placebo, pramipexole added to antidepressants reduces symptoms significantly at 12 weeks in treatment-resistant depression, a trial finds.

Introduction Major depressive disorder (MDD) is a major global healthcare challenge. This is, in part, due to the lack of treatment response and chronic course of MDD. Such a course of illness is ...

A compound best known for giving almonds and apricots their aroma may be the key to defeating hard-to-kill cancer cells. Japanese researchers found that benzaldehyde can stop the shape-shifting ...

One single psychiatrist has been approved to prescribe psilocybin or “magic mushrooms” for treatment-resistant depression. That psychiatrist is Professor Cameron Lacey, who welcomed the approval as an ...

Atai Life Sciences is making incremental progress towards opening door for a first psychedelic treatment for depression. Read ...

Life Sciences & Beckley Psytech announce positive results from phase 2b study of BPL-003 in patients with treatment-resistant depression: New York Wednesday, July 2, 2025, 10 ...

A European biotech company is stealing the show so far during Tuesday’s session after the company announced positive topline ...

Atai Life Sciences (NASDAQ: ATAI) and Beckley Psytech recently announced positive topline results from a phase 2b study of BPL-003 in patients with treatment-resistant depression (TRD). The study, ...

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the therapy.

Deep transcranial magnetic stimulation was safe and effective in treating adolescents and young adults with major depressive ...

The growing global burden of neuropsychiatric disorders is a critical driver for the treatment market. With over 9.1 million annual deaths attributed to neurological diseases and an additional 8 ...